Compare LGIH & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | CSTL |
|---|---|---|
| Founded | 2003 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2013 | 2019 |
| Metric | LGIH | CSTL |
|---|---|---|
| Price | $51.14 | $41.91 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $75.90 | $46.00 |
| AVG Volume (30 Days) | ★ 439.2K | 323.5K |
| Earning Date | 02-17-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.53 | N/A |
| Revenue | ★ $1,788,933,000.00 | $343,530,000.00 |
| Revenue This Year | N/A | $2.54 |
| Revenue Next Year | $18.60 | N/A |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | N/A | ★ 10.15 |
| 52 Week Low | $39.70 | $14.59 |
| 52 Week High | $97.25 | $43.01 |
| Indicator | LGIH | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 55.68 | 66.08 |
| Support Level | $50.95 | $39.74 |
| Resistance Level | $55.28 | $43.01 |
| Average True Range (ATR) | 3.12 | 1.72 |
| MACD | 0.49 | 0.06 |
| Stochastic Oscillator | 67.06 | 80.68 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company have seven operating segments ( West, Northwest, Central, Midwest, Florida, Southeast and Mid-Atlantic) that it aggregates into five qualifying reportable segment. Majority of the revenue is generated from Central division segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.